{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T08:42:20Z","timestamp":1795250540488,"version":"4.10.3"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Patients with immune-mediated inflammatory diseases (IMIDs) treated with immunosuppressive therapies are at higher risk for infections, including those preventable by vaccines. Among these therapies, Janus kinase inhibitors (JAK-is) are increasingly used, though their association with varicella zoster virus (VZV) reactivation raises concerns. The recombinant zoster vaccine (Shingrix\u2122) is recommended for immunocompromised individuals and has shown strong safety and efficacy; however, data on its immunogenicity in IMID patients\u2014especially those receiving JAK-is, anti-TNF agents or MTX\u2014remain limited. In the present study, we aimed to evaluate both humoral and cellular immune responses to the recombinant herpes zoster vaccine in IMID patients treated with different JAK inhibitors in comparison with IMID patients treated with \u2018conventional\u2019 therapies, i.e. anti-TNF and\/or MTX. We also sought to assess whether immune responses differ between patients receiving pan-JAK-is vs selective JAK1 inhibitors, and to identify clinical factors associated with reduced vaccine-induced immunity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study investigated both humoral (seroconversion rate, titer of VZV-specific IgG antibodies) and cellular CD4 T cell (IL-2 plus IFN-\u03b3) and CD8 T cell (Granzyme A and\/or Granzyme B) immune responses following a two-dose regimen of the recombinant inactivated vaccine in two cohorts of IMID patients treated with JAK-i or anti-TNF and\/or MTX. Immune responses were compared with responses in a cohort of healthy individuals matched by age and sex. We also sought to assess whether immune responses differ between patients receiving pan-JAK-is vs selective JAK1 inhibitors, and to identify clinical factors associated with reduced vaccine-induced immunity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 176 participants (mean age 58.6\u2009\u00b1\u20099.9\u2009years; 33% female) were included. Among them, 39 received non-selective JAK-is (14 baricitinib, 25 tofacitinib), 54 received selective JAK1 inhibitor (upadacitinib) and 46 were on anti-TNF and\/or MTX; 37 healthy individuals served as controls. Seroconversion was lower in JAK-i-treated patients (74%) compared with anti-TNF\/MTX (91%) and the controls (100%, P\u2009&amp;lt;\u20090.001). Median post-vaccination IgG titers were significantly lower in JAK-i-treated patients (1753\u2009\u00b1\u20091112\u2009mIU\/ml) than in the anti-TNF\/MTX patients (2874\u2009\u00b1\u20091020\u2009mIU\/ml) and the controls (3185\u2009\u00b1\u2009576\u2009mIU\/ml; P\u2009&amp;lt;\u20090.001). CD4 Th1 responses (IL-2\u2009+\u2009IFN-\u03b3) were observed in 28% of JAK-i patients, 67% of anti-TNF\/MTX patients and 95% of controls (P\u2009&amp;lt;\u20090.001). CD8 T cell responses were similarly impaired: 29% (JAK-i) vs 41% (anti-TNF\/MTX) vs 85% (controls) (P\u2009&amp;lt;\u20090.001). Non-selective JAK-is were associated with the poorest responses (baricitinib: 64% seroconversion; 0% CD4; 7% CD8), while upadacitinib-treated patients showed higher rates (83% seroconversion; 39% CD4; 39% CD8). Granzyme A\/B, IL-2 and IL-6 levels post-vaccination were significantly higher in anti-TNF\/MTX patients than in the JAK-i groups. Immunogenicity negatively correlated with cumulative glucocorticoid and MTX doses, longer JAK-i exposure and history of \u22652 DMARDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study highlights impaired immune responses to the recombinant herpes zoster vaccine in IMID patients treated with JAK-is. These patients showed significantly reduced humoral and cellular responses, suggesting lower protection against VZV reactivation. While anti-TNF\/MTX-treated patients had mildly reduced responses compared with controls, their immunogenicity was relatively preserved. In contrast, JAK-i-treated patients had markedly lower antibody titers and T cell responses. Notably, this impairment was more pronounced with non-selective JAK-is than with selective JAK1 inhibitors, underscoring differences within the JAK-i class.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf533","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:22:32Z","timestamp":1760530952000},"source":"Crossref","is-referenced-by-count":6,"title":["Differences in immunogenicity to zoster recombinant vaccine in IMID patients undergoing treatment with non-selective or selective JAK-i"],"prefix":"10.1093","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0889-9877","authenticated-orcid":false,"given":"Cristiana","family":"Sieiro Santos","sequence":"first","affiliation":[{"name":"Rheumatology Department, Complejo Asistencial Universitario de Le\u00f3n , Le\u00f3n,","place":["Spain"]},{"name":"Biomedical Sciences Department, Institute of Biomedicine (IBIOMED), Unversity of Le\u00f3n , Le\u00f3n,","place":["Spain"]},{"name":"Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester , Manchester,","place":["UK"]},{"name":"Rheumatology Department, Manchester University NHS Foundation Trust (MFT) , Manchester,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Garcia","family":"Herrero","sequence":"additional","affiliation":[{"name":"Immunology Department, Complejo Asistencial Universitario de Le\u00f3n , Le\u00f3n,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Ordas Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Complejo Asistencial Universitario de Le\u00f3n , Le\u00f3n,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"\u00c1lvarez Castro","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Complejo Asistencial Universitario de Le\u00f3n , Le\u00f3n,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"L\u00f3pez Robles","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Complejo Asistencial Universitario de Le\u00f3n , Le\u00f3n,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Colindres","sequence":"additional","affiliation":[{"name":"Immunology Department, Complejo Asistencial Universitario de Le\u00f3n , Le\u00f3n,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Sierra Ausin","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Complejo Asistencial Universitario de Le\u00f3n , Le\u00f3n,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda Robles","family":"Mart\u00edn","sequence":"additional","affiliation":[{"name":"Family Medicine, Centro de salud El Ejido , Le\u00f3n,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M","family":"Sahagun","sequence":"additional","affiliation":[{"name":"Instituto de Biomedicina Universidad de Le\u00f3n (IBIOMED), University of Le\u00f3n , Le\u00f3n,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose G","family":"Ruiz de Morales","sequence":"additional","affiliation":[{"name":"Biomedical Sciences Department, Institute of Biomedicine (IBIOMED), Unversity of Le\u00f3n , Le\u00f3n,","place":["Spain"]},{"name":"Immunology Department, Complejo Asistencial Universitario de Le\u00f3n , Le\u00f3n,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"2026020205390605900_keaf533-B1","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3390\/vaccines11091446","article-title":"Vaccination in the era of immunosuppression","volume":"11","author":"Alnaimat","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"2026020205390605900_keaf533-B2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026020205390605900_keaf533-B3","first-page":"700","article-title":"The evolution of immune-mediated inflammatory disease treatments: past, present, and future","volume":"22","author":"McInnes","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"2026020205390605900_keaf533-B4","first-page":"103290","article-title":"Immunosuppressive therapies and their impact on herpes zoster risk in autoimmune diseases","volume":"22","author":"Benucci","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2026020205390605900_keaf533-B5","doi-asserted-by":"crossref","first-page":"1241954","DOI":"10.3389\/fphar.2023.1241954","article-title":"Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026020205390605900_keaf533-B6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"2026020205390605900_keaf533-B7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"2026020205390605900_keaf533-B8","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","article-title":"Tofacitinib: a review in rheumatoid arthritis","volume":"77","author":"Dhillon","year":"2017","journal-title":"Drugs"},{"key":"2026020205390605900_keaf533-B9","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2026020205390605900_keaf533-B10","first-page":"399","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis: 1-year results from a phase II\/III study","volume":"74","author":"Mease","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026020205390605900_keaf533-B11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jdin.2024.09.012","article-title":"Risk of infections during treatment with oral Janus kinase inhibitors in randomized placebo-controlled trials: a systematic review and meta-analysis","volume":"18","author":"Isufi","year":"2025","journal-title":"JAAD Int"},{"key":"2026020205390605900_keaf533-B12","doi-asserted-by":"crossref","first-page":"152120","DOI":"10.1016\/j.semarthrit.2022.152120","article-title":"Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: a structured literature review","volume":"58","author":"Winthrop","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"2026020205390605900_keaf533-B13","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2026020205390605900_keaf533-B14","doi-asserted-by":"crossref","first-page":"1759720X20936059","DOI":"10.1177\/1759720X20936059","article-title":"JAK inhibitors and infections risk: focus on herpes zoster","volume":"12","author":"Sunzini","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2026020205390605900_keaf533-B15","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.3390\/jcm13113121","article-title":"Increased risk of herpes zoster in rheumatoid arthritis not only due to JAK inhibitors-study of 392 patients from single university center","volume":"13","author":"Dom\u00ednguez-Casas","year":"2024","journal-title":"J Clin Med"},{"key":"2026020205390605900_keaf533-B16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.revmed.2024.10.452","article-title":"JAK inhibitors (JAKi): mechanisms of action and perspectives in systemic and autoimmune diseases","volume":"46","author":"Chikhoune","year":"2025","journal-title":"Rev Med Interne"},{"key":"2026020205390605900_keaf533-B17","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of Janus Kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205390605900_keaf533-B18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2217\/imt-2018-0113","article-title":"Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis","volume":"11","author":"Zhang","year":"2019","journal-title":"Immunotherapy"},{"key":"2026020205390605900_keaf533-B19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/annrheumdis-2021-220822","article-title":"Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials","volume":"81","author":"Winthrop","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026020205390605900_keaf533-B20","doi-asserted-by":"crossref","first-page":"e172634","DOI":"10.1172\/JCI172634","article-title":"Recruitment of naive CD4+ T cells by the recombinant zoster vaccine correlates with persistent immunity","volume":"133","author":"Laing","year":"2023","journal-title":"J Clin Invest"},{"key":"2026020205390605900_keaf533-B21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026020205390605900_keaf533-B22","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1093\/rheumatology\/keae584","article-title":"Immunogenicity to herpes zoster recombinant subunit vaccine in immune-mediated rheumatic patients under treatment with JAK inhibitors","volume":"64","author":"Sieiro Santos","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205390605900_keaf533-B23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story","volume":"83","author":"Bonelli","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026020205390605900_keaf533-B24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41584-024-01153-1","article-title":"JAK inhibitor selectivity: new opportunities, better drugs?","volume":"20","author":"Virtanen","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"2026020205390605900_keaf533-B25","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1002\/art.42547","article-title":"Differences in JAK isoform selectivity among different types of JAK inhibitors evaluated for rheumatic diseases through in vitro profiling","volume":"75","author":"Virtanen","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026020205390605900_keaf533-B26","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1093\/rheumatology\/kead552","article-title":"Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors","volume":"63","author":"K\u00e4llmark","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205390605900_keaf533-B27","doi-asserted-by":"crossref","first-page":"e003902","DOI":"10.1136\/rmdopen-2023-003902","article-title":"Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with DMARDs","volume":"10","author":"Kojima","year":"2024","journal-title":"RMD Open"},{"key":"2026020205390605900_keaf533-B28","doi-asserted-by":"crossref","first-page":"6967","DOI":"10.3390\/ijms24086967","article-title":"Immunogenicity and safety of adjuvanted recombinant zoster vaccine in rheumatoid arthritis patients on anti-cellular biologic agents or JAK inhibitors: a prospective observational study","volume":"24","author":"Venerito","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026020205390605900_keaf533-B29","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1007\/s10067-024-07041-z","article-title":"Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study","volume":"43","author":"Chen","year":"2024","journal-title":"Clin Rheumatol"},{"key":"2026020205390605900_keaf533-B30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/annrheumdis-2024-eular.763","article-title":"Immunogenicity of an adjuvant recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomized substudy","volume":"83","author":"Winthrop","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026020205390605900_keaf533-B31","doi-asserted-by":"crossref","first-page":"e001898","DOI":"10.1136\/rmdopen-2021-001898","article-title":"Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases","volume":"8","author":"Sieiro Santos","year":"2022","journal-title":"RMD Open"},{"key":"2026020205390605900_keaf533-B32","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.vaccine.2009.01.136","article-title":"Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults","volume":"27","author":"McElhaney","year":"2009","journal-title":"Vaccine"},{"key":"2026020205390605900_keaf533-B33","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.4049\/jimmunol.176.10.6333","article-title":"T cell responses are better correlates of vaccine protection in the elderly","volume":"176","author":"McElhaney","year":"2006","journal-title":"J Immunol"},{"key":"2026020205390605900_keaf533-B34","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1136\/annrheumdis-2014-205615","article-title":"Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro","volume":"73","author":"Wang","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026020205390605900_keaf533-B35","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/art.40780","article-title":"Evaluation of the short-, mid-, and long-term effects of tofacitinib on lymphocytes in patients with rheumatoid arthritis","volume":"71","author":"van Vollenhoven","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026020205390605900_keaf533-B36","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/art.40680","article-title":"Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis","volume":"70","author":"Tanaka","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2026020205390605900_keaf533-B37","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/annrheumdis-2014-206028","article-title":"The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis","volume":"74","author":"Boyle","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026020205390605900_keaf533-B38","doi-asserted-by":"crossref","first-page":"e941878","DOI":"10.12659\/MSM.941878","article-title":"Serum inflammatory cytokine levels in herpes zoster patients and their association with postherpetic neuralgia: a prospective study","volume":"29","author":"Gu","year":"2023","journal-title":"Med Sci Monit"},{"key":"2026020205390605900_keaf533-B39","doi-asserted-by":"crossref","first-page":"e0150301","DOI":"10.1371\/journal.pone.0150301","article-title":"Evaluation of chosen cytokine levels among patients with herpes zoster as ability to provide immune response","volume":"11","author":"Zajkowska","year":"2016","journal-title":"PLoS One"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf533\/64717850\/keaf533.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf533\/64717850\/keaf533.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf533\/64717850\/keaf533.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T10:39:19Z","timestamp":1770028759000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keaf533\/8287647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf533","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,10,16]]},"article-number":"keaf533"}}